Mesoblast Ltd Asset Resilience Ratio

Latest as of June 2023: 0.00%

Mesoblast Ltd asset resilience ratio. Mesoblast Ltd (MSB) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Mesoblast Ltd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$-2.00K

≈ $-1.42K USD Cash + Short-term Investments

Total Assets

AU$669.41 Million

≈ $473.65 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Mesoblast Ltd (2013–2023)

Asset resilience ratio of Mesoblast Ltd from 2013 to 2023. This chart shows how Mesoblast Ltd's Asset Resilience Ratio has changed over time. Read Mesoblast Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Mesoblast Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MSB total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$-2.00K	-0.0%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$-2.00K	0.00%

Asset Resilience Insights

Limited Liquidity: Mesoblast Ltd maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Mesoblast Ltd Industry Peers by Asset Resilience Ratio

Compare Mesoblast Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Mesoblast Ltd Asset Resilience Ratio by Year (2013–2023)

Mesoblast Ltd asset resilience ratio by year from 2013 to 2023. The table below shows the annual Asset Resilience Ratio data for Mesoblast Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-06-30	0.00%	AU$-2.00K ≈ $-1.42K	AU$669.41 Million ≈ $473.65 Million	0.00pp
2022-06-30	0.00%	AU$13.00K ≈ $9.20K	AU$662.14 Million ≈ $468.51 Million	+0.01pp
2021-06-30	-0.01%	AU$-49.00K ≈ $-34.67K	AU$744.72 Million ≈ $526.93 Million	-0.01pp
2020-06-30	0.00%	AU$12.00K ≈ $8.49K	AU$733.60 Million ≈ $519.07 Million	0.00pp
2019-06-30	0.00%	AU$21.00K ≈ $14.86K	AU$652.12 Million ≈ $461.41 Million	-0.05pp
2018-06-30	0.06%	AU$392.00K ≈ $277.36K	AU$692.44 Million ≈ $489.95 Million	-5.71pp
2017-06-30	5.76%	AU$37.79 Million ≈ $26.74 Million	AU$655.69 Million ≈ $463.94 Million	+5.40pp
2013-06-30	0.36%	AU$3.19 Million ≈ $2.26 Million	AU$883.71 Million ≈ $625.28 Million	--

pp = percentage points

About Mesoblast Ltd

AU:MSB Australia Biotechnology

Market Cap

$1.93 Billion

AU$2.72 Billion AUD

Market Cap Rank

#6093 Global

#145 in Australia

Share Price

AU$2.10

Change (1 day)

-2.78%

52-Week Range

AU$1.76 - AU$3.07

All Time High

AU$5.21